Employees: 1,545
Size Edding Genor (6998.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $410M, the 798th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$1.57 on 18 Nov 2026.
Performance Over six months the shares fell 34.6%, against -22.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 1,417.7% over the last twelve months (peer median +5.9%); the operating margin is 26.2% (peer median -7.2%).
Valuation It trades at 1.0× enterprise value to sales against a peer median of 5.6× (cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +197%, so the hurdle is -213 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.5 points above its cost of capital (8.9% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$3.68B | HK$2.70B | HK$2.76B | HK$0 | HK$18.5M |
| Revenue growth | — | -2% | — | -100% | — |
| Gross profit | HK$2.59B | HK$1.76B | HK$1.78B | -HK$85.0M | -HK$45.0M |
| EBITDA | n/a | HK$954M | HK$924M | -HK$687M | -HK$852M |
| Net income | HK$421M | HK$433M | HK$421M | -HK$745M | -HK$849M |
| Free cash flow | HK$616M | HK$236M | HK$688M | -HK$471M | -HK$686M |
| Capital expenditure | HK$61.4M | HK$51.7M | HK$218M | HK$1.14M | HK$15.1M |
| Total debt | n/a | HK$1.66B | HK$2.16B | HK$7.88M | HK$32.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6998.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.4% | -13.4% | 5th highest of 21 |
| 6-month return | -34.6% | -22.0% | 4th lowest of 21 |
| Distance from 52-week high | -59.7% | -40.6% | 4th lowest of 21 |
| Revenue growth (TTM) | +1,417.7% | +5.9% | highest of 17 |
| Operating margin | 26.2% | -7.2% | 4th highest of 17 |
| EV / Sales | 1.0× | 5.6× | cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -15.3% | 4.0% | 3rd least demanding of 8 |
| Growth delivered (Del g) | +197.3% | +4.7% | highest of 7 |
| Hurdle (Req g minus delivered) | -212.7 pp | +15.8 pp | least demanding of 7 |
| ROIC minus cost of capital | +7.5 pp | -8.4 pp | 3rd highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | 1.0× | -15.3% | +197.3% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | 10.3× | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | 10.6× | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 1.9× | -18.8% | -36.1% |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | 908.6× | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | 215.1× | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $402M | -22% | -17% | -16% | 10.9× | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | 2.9× | 4.0% | -62.3% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $396M | -33% | n/a | n/a | n/a | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 14.6× | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | 5.2× | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 12.3× | 5.3% | +70.5% |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 2.6× | -19.5% | n/a |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | 3.1× | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $391M | -20% | +6% | -2% | 1.7× | 36.6% | +8.9% |
| Polynovo PNV.AX | Australia | $388M | -34% | +13% | 5% | 3.9× | 51.9% | +37.6% |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 4.0× | 2.1% | +0.5% |
| Hubei Goto Biopharm 300966.SZ | China | $386M | -16% | +6% | -10% | 6.0× | n/a | n/a |